Composition for improving respiratory health and treating or preventing respiratory diseases comprising vitamin b5, pharmaceutical composition for treating or preventing respiratory diseases comprising same, and health functional food composition for improving respiratory health or respiratory diseases comprising same

Abstract

The present invention relates to: a composition for improving respiratory health and treating or preventing respiratory diseases, comprising vitamin B5; a pharmaceutical composition for treating or preventing respiratory diseases, comprising same; and a health functional food composition for improving respiratory health or respiratory diseases, comprising same.

Description

Composition for improving respiratory health and treating or preventing respiratory diseases, including vitamin B5, pharmaceutical composition for treating or preventing respiratory diseases, including the same, and health functional food composition for improving respiratory health or respiratory diseases, including the same

[0001] The present invention relates to a composition for improving respiratory health and treating or preventing respiratory diseases, including vitamin B5, a pharmaceutical composition for treating or preventing respiratory diseases, including the same, and a health functional food composition for improving respiratory health or respiratory diseases, including the same.

[0002] Health functional foods are typically taken orally in capsules, tablets, or other forms. However, taking health functional foods orally poses the risk of decomposition or excretion of the ingredients during absorption, metabolism, and decomposition.

[0003] Meanwhile, oral administration of vitamin B5 has been shown to improve various health benefits, including hair loss prevention, stress relief, depression relief, immune system enhancement, and anemia prevention. While the recommended daily intake for adults is 10 mg, the recommended daily oral dose for humans is 100-1,000 mg, requiring high doses. Research on other methods of vitamin B5 administration is limited.

[0004] The present invention aims to solve the above problems by providing a composition containing vitamin B5 as an active ingredient, which improves respiratory health even in small amounts, has a respiratory protection effect, and has an effect of improving, preventing, and treating respiratory diseases.

[0005]

[0006] However, the problems to be solved by the present invention are not limited to those mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.

[0007] According to one embodiment of the present invention, a composition for improving respiratory health and treating or preventing respiratory diseases is provided, comprising vitamin B5 as an active ingredient.

[0008] According to another embodiment of the present invention, a pharmaceutical composition for treating or preventing a respiratory disease is provided, comprising a composition for improving respiratory health and treating or preventing a respiratory disease according to one embodiment of the present invention.

[0009] According to another embodiment of the present invention, a health functional food composition for improving respiratory health or respiratory disease is provided, comprising a composition for improving respiratory health and treating or preventing respiratory disease according to one embodiment of the present invention.

[0010] The composition of the present invention can reduce the total cell count, inflammatory cells, and inflammatory cytokines in bronchopulmonary lavage fluid, thereby improving respiratory health, improving respiratory diseases including respiratory inflammation, allergies, and asthma, and protecting against respiratory damage caused by fine dust or pathogens. Furthermore, the present invention utilizes an inhalation method, so that it can have the above-mentioned effects of improving respiratory health and treating or preventing respiratory diseases even with a smaller amount than when administered orally.

[0011]

[0012] The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the detailed description of the present invention or the composition of the invention described in the claims.

[0013] Figure 1 shows the results of evaluating the total number of cells in bronchial lung washing fluid according to examples and comparative examples of the present invention.

[0014] Figure 2 shows the results of evaluating the inhibitory effect of inflammatory cells (neutrophils) in bronchial lavage fluid according to examples and comparative examples of the present invention.

[0015] Figure 3 shows the results of confirming the number of neutrophils in bronchial lavage fluid according to examples and comparative examples of the present invention using an immunofluorescence staining (FACS) marker.

[0016] Figure 4 shows the results of confirming the reduction of the inflammatory factor cytokine IL-6 in bronchial lavage fluid according to the examples and comparative examples of the present invention.

[0017] Below, embodiments are described in detail with reference to the attached drawings. However, the embodiments may be modified in various ways, and the scope of the patent application is not limited or restricted by these embodiments. It should be understood that all modifications, equivalents, or alternatives to the embodiments are included within the scope of the patent application.

[0018] The terms used in the examples are for illustrative purposes only and should not be construed as limiting. Singular expressions include plural expressions unless the context clearly dictates otherwise. In this specification, terms such as "comprise" or "have" are intended to indicate the presence of a feature, number, step, operation, component, part, or combination thereof described in the specification, but should be understood to not preclude the possibility of the presence or addition of one or more other features, numbers, steps, operations, components, parts, or combinations thereof.

[0019] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the art to which the embodiments pertain. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and shall not be interpreted in an idealized or overly formal sense unless explicitly defined herein.

[0020] In addition, when describing with reference to the attached drawings, identical components will be assigned the same reference numerals regardless of the drawing numbers, and redundant descriptions thereof will be omitted. When describing embodiments, if a detailed description of a related known technology is judged to unnecessarily obscure the gist of the embodiment, the detailed description will be omitted.

[0021] Additionally, in describing components of an embodiment, terms such as first, second, A, B, (a), (b), etc. may be used. These terms are only intended to distinguish the components from other components, and the nature, order, or sequence of the components are not limited by the terms.

[0022] Components included in one embodiment and components with common functions will be described using the same names in other embodiments. Unless otherwise stated, the descriptions given in one embodiment can be applied to other embodiments, and detailed descriptions will be omitted to the extent of overlap.

[0023] Throughout the specification, when a part is said to "include" a component, this does not mean that it excludes other components, but rather that it may include other components.

[0024]

[0025] According to one embodiment of the present invention, a composition for improving respiratory health and treating or preventing respiratory diseases, comprising vitamin B5 (pantothenic acid) as an active ingredient, can be provided.

[0026] Vitamin B5, a water-soluble member of the vitamin B complex, is essential for the production of collagen, a key component of skin and hair. It also helps break down lipids, preventing oily skin and promoting clear skin and healthy hair. Vitamin B5 can also help prevent hair loss, relieve stress, alleviate depression, boost immunity, and prevent anemia. It also has anti-inflammatory properties.

[0027] The terms "improvement" or "treatment" in the present invention may refer to any action that improves or beneficially alters the symptoms of respiratory health or disease by administering the composition. Furthermore, the term "prevention" refers to any action that inhibits or delays the onset, spread, or recurrence of a respiratory disease by administering the composition of the present invention.

[0028] The term "respiratory system" in the present invention refers to an organ capable of inhaling oxygen from the air and exhaling carbon dioxide produced as a result of energy metabolism, and may refer to the airways, bronchi, lungs, and lungs. If the cells or tissues of these respiratory organs are invaded by any substance that causes a change in their structure, such as due to bacteria, viruses, smoking, air pollution, etc., inflammation may occur as a defense response of the body to repair or regenerate the damaged area. This series of reactions includes local blood vessels, various tissue cells of body fluids, and immune-related cells.

[0029] The term "respiratory disease" in the present invention refers to negative symptoms that may occur in the respiratory system, and the respiratory disease is not limited to any disease that is manifested by inflammation in the respiratory system, but may be, for example, one or more diseases selected from the group consisting of allergies, bronchitis, sinusitis, lower respiratory tract infection, bronchiolitis, asthma, chronic obstructive pulmonary disease, rhinitis, pneumonia, emphysema, bronchiectasis, pulmonary fibrosis, cough, phlegm, pharyngitis, tonsillitis, and laryngitis.

[0030] In addition, the composition of the present invention may have an improving effect on the deterioration of respiratory health that may be caused by external factors such as fine dust, pathogens, and viruses. In the present invention, "improving respiratory health" means reducing the intensity and frequency of one or more respiratory symptoms selected from the group consisting of swollen tonsils, sore throat, cough, sneezing, phlegm, sore throat, stuffy nose, and hoarse voice, eliminating respiratory symptoms, or preventing respiratory symptoms.

[0031] The composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention may be used on any animal, including humans, that has developed or is at risk of developing respiratory diseases. The animals may include, but are not limited to, cows, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, rats, mice, and the like, as well as humans, requiring treatment for similar symptoms.

[0032]

[0033] A composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention may be applied to inflammation by inhalation or spraying.

[0034] At this time, the inhalation or spray may be applied to the oral or nasal cavity. Preferably, the effect is enhanced by inhaling or spraying the compound through the oral cavity, thereby directly applying fine droplets around the throat, where respiratory inflammation is a major concern. The present invention, when administered by inhalation or spray, can avoid metabolism (decomposition) in body tissues and is immediately absorbed, thereby improving and treating respiratory inflammation with a smaller dose.

[0035] The above inhalation or spraying may be applied by any of ultrasound, spray, or nebulizing devices. In this case, the composition for improving respiratory health and treating or preventing respiratory diseases may be administered to the user from the device via heating, ultrasound, surface waves, or other methods, but is not limited to the methods described. In particular, when administered via heating, the delivery efficiency and speed of the composition for improving respiratory health and treating or preventing respiratory diseases of the present invention may increase.

[0036]

[0037] In a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention, the composition for improving respiratory health and treating or preventing respiratory diseases can be formulated and used in an inhalable form according to a conventional method.

[0038] For example, the composition for improving respiratory health and treating or preventing respiratory diseases may be in the form of a liquid or sprayable form. If the composition of the present invention is in the form of a liquid, it may be aerosolized and sprayed through methods such as heating, ultrasound, or surface waves.

[0039]

[0040] In a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention, the dosage may be 1 mg / kg to 30 mg / kg.

[0041] The daily oral dose of vitamin B5 for humans may be as high as 50 mg / kg or more, but in the present invention, even a lower dose can be administered by inhalation, thereby providing excellent respiratory inflammation improvement and treatment effects.

[0042] The present invention can have an effect of improving respiratory health and treating or preventing respiratory diseases within the numerical range of the dosage described above. Preferably, the dosage of the composition for improving respiratory health and treating or preventing respiratory diseases may be 1 mg / kg to 30 mg / kg, preferably 5 mg / kg to 28 mg / kg, and more preferably 8 mg / kg to 28 mg / kg. If the dosage of the present invention is less than the numerical range described above, the effect of improving and treating respiratory diseases may be minimal. On the other hand, even if the dosage of the present invention exceeds the numerical range described above, the effect of improving, treating, and preventing respiratory diseases is not further enhanced.

[0043]

[0044] The dosage of a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention can be achieved, for example, by controlling the concentration, administration time, administration frequency, etc. of the composition.

[0045] For example, in a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention, the concentration of vitamin B5 may be 2 wt% to 30 wt%, preferably 5 wt% to 25 wt%, and more preferably 10 wt% to 20 wt%, relative to the total weight of the composition for improving respiratory health and treating or preventing respiratory diseases, and the administration time may be 5 minutes to 60 minutes. However, the method for achieving the administration dosage is not limited to the described examples.

[0046]

[0047] According to one embodiment of the present invention, a health functional food composition for improving respiratory health or respiratory disease, including a composition for improving respiratory health and treating or preventing respiratory disease, can be provided.

[0048] The above health functional food composition refers to a food manufactured and processed using raw materials or ingredients with functionality useful to the human body according to Act No. 6727 on Health Functional Foods, and “functionality” means consumption for the purpose of obtaining a useful effect for health purposes such as regulating nutrients for the structure and function of the human body or physiological action.

[0049]

[0050] According to one embodiment of the present invention, a pharmaceutical composition for treating or preventing a respiratory disease can be provided, comprising a composition for improving respiratory health and treating or preventing a respiratory disease.

[0051] A pharmaceutical composition refers to a composition manufactured for the purpose of preventing or treating a disease. The composition for improving respiratory health and treating or preventing respiratory diseases may be used alone or in combination with other pharmaceutically active compounds that exhibit preventive and therapeutic effects against respiratory inflammatory diseases, or in an appropriate combination.

[0052]

[0053] According to one embodiment of the present invention, a method for treating or preventing a respiratory disease can be provided, which comprises administering a pharmaceutical composition for treating or preventing the respiratory disease to a subject. The subject may refer to any animal, including humans, and may include, but is not limited to, humans, cows, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, rats, mice, etc.

[0054] According to one embodiment of the present invention, the pharmaceutical composition for treating or preventing a respiratory disease can be used for treating or preventing a respiratory disease.

[0055]

[0056] Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following examples.

[0057]

[0058] 1. Preparation of an inhalation composition for improving and treating respiratory inflammation

[0059] Vitamin B5 (Pantothenic Acid, 0412678, DSM, UK) 25, 100, and 200 g were respectively measured and placed in 1 L beakers, 700 mL of primary distilled water was added, and mixed for 15 minutes using a stirrer. After adjusting the total amount to 1,000 mL with primary distilled water, the mixture was mixed for 15 minutes to prepare an inhalation composition for improving and treating respiratory inflammation containing vitamin B5 at concentrations of 2.5, 10, and 20%.

[0060]

[0061] 2. Preparation of an oral composition for improving and treating respiratory inflammation

[0062] To administer low, medium, and high doses of vitamin B5 (Pantothenic Acid, 0412678, DSM, UK) orally, 150, 300, and 600 mg of vitamin B5 were measured and placed into 250 ml glass bottles, respectively. 100 ml of primary distilled water was added to each 250 ml glass bottle, and a stirrer was used to mix for 15 minutes to prepare an oral composition for improving and treating respiratory inflammation. The test substances prepared for each dose were orally administered using a gastric sonde at a dosage of 10 ml / kg.

[0063]

[0064] 3. Preparation of a respiratory injury model administered with a composition for improving and treating respiratory inflammation.

[0065] (1) Laboratory animals

[0066] Balb / c mice (male, 6 weeks old, weighing 15–17 g) were purchased from Coretech after receiving approval from the Institutional Animal Care and Use Committee (IACUC). After acclimatization for one week in the breeding room of the KT&G Bio-Efficacy Evaluation Center (temperature 23±2°C, humidity 50±10%, 12-h light / dark cycle), they were used in the experiment.

[0067]

[0068] (2) Preparation of test substances to induce respiratory damage model

[0069] A PM10D mixture was prepared by diluting 3 mg / mL of fine dust particles [Particulate Matter 10 (PM10), ERM-CZ120, Sigma Aldrich, St. Louis, MO, USA] and 0.6 mg / mL of diesel particulate matter [Diesel Particulate Matter (DEP), NIST-2975, Sigma Aldrich, St. Louis, MO, USA] in 1% Alum (Aluminium Hydroxide, 239186, Sigma Aldrich, USA).

[0070]

[0071] (3) Creation of a respiratory damage model

[0072] After the experimental animals were anesthetized with isoflurane, 50 ㎕ of PM10D was administered to each of the nose and mouth (total of 100 ㎕) three times (on days 3, 6, and 9 after test substance administration) to create a respiratory tract injury inflammation model.

[0073]

[0074] (4) Preparation of a respiratory injury model administered with a composition for improving and treating respiratory inflammation

[0075] Each group used 5 to 6 animals, and for Comparative Examples 1 and 2, normal animals that were not treated at all (normal group), a respiratory tract injury inflammation model group (induced group) that was administered purified water (60 min / day) by inhalation after PM10D administration, and the oral administration groups of Comparative Examples 3 to 5 were prepared. For Examples 1 to 8, after PM10D treatment, vitamin B5 2.5, 10, and 20% were administered by inhalation for 10 days at each dose (mg / kg) by adjusting the administration time to compare the inflammation improvement effect. The inhalation administration was performed using a mist generator. The administration dose was calculated by converting the exposure amount of the aerosol (mg / L) into the administration dose (mg / kg) using the calculation formula according to the previous literature (Alexander et al., Inhal Toxicol. 2008 Oct;20(13):1179-89.).

[0076]

[0077] Group Vitamin B5 Concentration (%) Administration Time (min) Comparative Example 1 Normal Group--Comparative Example 2 Induced Group Vitamin B5 Instead of Purified Water Administration 60 Comparative Example 315 mg / kg (Oral Administration Group)--Comparative Example 430 mg / kg (Oral Administration Group)--Comparative Example 560 mg / kg (Oral Administration Group)--Example 11 ㎎ / ㎏ 2.5 10 Example 22 ㎎ / ㎏ 10 7 Example 36 ㎎ / ㎏ 10 20 Example 410 ㎎ / ㎏ 10 37 Example 510 ㎎ / ㎏ 20 22 Example 612 ㎎ / ㎏ 20 26 Example 717 ㎎ / ㎏ 10 60 Example 828 ㎎ / ㎏ 20 60

[0078]

[0079] 4. Experimental Example 1: Evaluation of the total cell count in bronchial lung lavage fluid

[0080] The total cell count in the bronchoalveolar lavage fluid (BALF) of Examples 1 to 8 and Comparative Examples 1 to 5 was investigated. The investigation method is as follows.

[0081] In Examples 1 to 8 and Comparative Examples 1 to 5, the experimental animals were anesthetized with isoflurane on the 11th day after the end of administration, blood was collected, the trachea was exposed, a syringe containing 1 mL of phosphate buffer saline (Phosphate Buffer Saline, 10010-023, Gibco, UK) was inserted into the trachea, and then secured with a thread. Bronchoalveolar lavage fluid was obtained by repeating this process three times using the phosphate buffer saline. After centrifugation (1500 RPM / 4 ℃ / 10 min) of the obtained bronchoalveolar lavage fluid, the supernatant was stored in an ultra-low temperature freezer (-70 ℃) to measure cytokines, and the cells isolated from the bronchoalveolar lavage fluid were treated with ACK (Ammonium-Chloride-Potassium buffer, A10492-01, Gibco, NY, USA) solution for 10 min to lyse red blood cells, and then washed again using phosphate buffer solution, and the total cell number was measured using a hematocytometer.

[0082] The results obtained from the above experiment were recorded as the mean ± standard deviation, and statistical analysis was performed using one-way ANOVA using GraphPad Prism 9.5 (GraphPad Software, Inc., Lajolla, CA, USA) to determine statistically significant variance. If significance was recognized, multiple analysis comparison method (Dunnett's multiple comparison test) was used. P value <0.05 ( * ), <0.01( ** ), <0.001( *** ), or <0.0001( **** ) significance test was performed at the level below.

[0083] The results are shown in Table 2 below and Figure 1.

[0084]

[0085] Comparison of the group with the classification-induced group (%): 17.2±3.5 ****Comparative Example 2100 Comparative Example 395.4±16.3 Comparative Example 4100.9±24.6 Comparative Example 593.1±16.2 Example 193.2±25.6 Example 275.5±21.2 Example 386.3±23.5 Example 455.2±16.5 **** Example 561.4±8.2 *** Example 663.1±20.6 **** Example 764.6±9.2 **** Example 863.9±15.8 ****

[0086]

[0087] According to Table 2 and Figure 1, the total number of cells in the bronchial lung washing fluid decreased in Examples 2 to 8 compared to Comparative Examples 2 to 5, and in particular, the total number of cells in the bronchial lung washing fluid in Examples 3 to 8 was significantly reduced compared to Comparative Example 2 or Comparative Examples 3 to 5. That is, the total number of cells in the bronchial lung washing fluid decreased compared to the induced group and the oral administration group when vitamin B5 was inhaled at 6 mg / kg or more. Through this, it was confirmed that when vitamin B5 is administered at a certain dose or more, it contributes to reducing the inflammation index, and in particular, the inflammation index reduction effect is excellent when inhaled.

[0088]

[0089] 5. Experimental Example 2: Evaluation of the Inhibitory Effect of Inflammatory Cells (Neutrophils) in Bronchopulmonary Lavage Fluid

[0090] The inhibitory effect of inflammatory cells in the bronchial lung washing fluids of Examples 1 to 8 and Comparative Examples 1 to 5 was evaluated. The evaluation method is as follows.

[0091] After smearing the bronchopulmonary washings on the slide, Diff-Quik (38721, Sysmex, Japan) staining was performed according to the manufacturer's manual, and 200 monocytes and polynucleated cells were counted using an optical microscope at 400x magnification. The change in the number of neutrophils was confirmed through Diff-Quik staining, and the results obtained from the above experiment were recorded as the mean ± standard deviation, and the P value was <0.05 ( * ), <0.01( ** ), <0.001( *** ), or <0.0001( **** ) significance test was performed at the level below.

[0092] The results are shown in Table 3 below and Figure 2.

[0093]

[0094] Comparison of the group with the classification-induced group (%): 10.1±0.1 **** Comparative Example 2100 Comparative Example 386.3±11.3 Comparative Example 489.4±23.5 Comparative Example 575.8±14.1 * Example 180.1±27.5 * Example 271.4±23.3 *** Example 384.6±24.3 * Example 444.1±14.6 **** Example 543.0±8.2 **** Example 661.0±22.7 **** Example 752.1±2.7 **** Example 854.7±12.9 ****

[0095]

[0096] As can be seen in Table 3 and Fig. 2, in Comparative Example 2, when a fine dust model was induced in experimental animals with PM10D, the number of neutrophils significantly increased, confirming that PM10D increased the level of inflammation in the respiratory tract. In addition, it was confirmed that the number of neutrophils decreased only when administered orally at a high dose of 60 mg / kg or more.

[0097] However, when vitamin B5 was administered by inhalation in Examples 1 to 8, it was confirmed that the number of neutrophils decreased compared to Comparative Example 2, and an excellent decrease in the number of neutrophils was confirmed in Examples 1 to 8 administered by inhalation compared to Comparative Examples 3 and 4, and only when administered at a high dose of 60 mg / kg or more, a phenomenon in which neutrophils decreased similarly to inhalation administration was confirmed, confirming that the composition of the present invention can secure an excellent effect even at a low dose. In particular, it was confirmed that the number of neutrophils decreased to a significant level in Examples 3 to 8.

[0098]

[0099] 6. Experimental Example 3: Confirmation of the Effect Using Immunofluorescent Markers in Bronchopulmonary Lavage Fluid

[0100] The number of neutrophils (CD11b+Gr-1+Siglec-F-) in the bronchial lung lavage fluids of Examples 2 to 6 and 8 and Comparative Examples 1 to 5 was investigated using an immunofluorescent staining marker. The investigation method is as follows.

[0101] For flow cytometry analysis, cells obtained from bronchopulmonary lavage fluid were washed in FACS buffer (PBS with 1.5% FBS), and then fluorescent substances capable of staining live / dead cells and FACS antibodies recognizing cell surface markers were diluted in FACS buffer and incubated at 4°C for 20 minutes. Information on the fluorescent substances and antibodies used is as follows.

[0102] Product NameDilution RatioManufacturerCat. NoFITC anti-mouse CD4 Antibody (GK1.5)1:300BioLegend100405PerCP / Cy5.5 anti-mouse CD8a Antibody (53-6.7)1:300BioLegend100733PE anti-mouse / human CD44 Antibody (IM7)1:300BioLegend103023PE / Cyanine7 anti-mouse CD62L Antibody (MEL-14)1:300BioLegend104417APC anti-mouse CD69 Antibody (H1.2F3)1:300BioLegend104513Alexa Fluor® 488 Rat Anti-Mouse Siglec-F (E50-2440)1:300BD Biosciences567005PE anti-mouse Ly-6G / Ly-6C (Gr-1) Antibody (RB6-8C5)1:300BioLegend108407APC anti-mouse / human CD11b Antibody (M1 / 70)1:300BioLegend101211Ghost DyeJjeem Red 780 Fixable Viability Dye1:1000Cell Signaling Technology18452S

[0103]

[0104] After incubation, the cells were washed with FACS buffer and fixed with fixation buffer (1% PFA, 4% PFA solution diluted 1 / 4 in PBS). Samples were acquired and fluorescence signals were detected using a FACS CantoⅡ (BD Biosciences, San Diego, CA, USA) device and analyzed using FlowJo (Treestar) software. The number of CD11b+Gr-1+Siglec-F- cells was measured, and the results obtained from the above experiment were reported as the mean ± standard deviation, and the P value was <0.05 ( * ) or <0.01( **) significance test was performed at the level below.

[0105] The results are shown in Table 5 below and Figure 3.

[0106]

[0107] Comparison of the group with the classification-induced group (%): 10.2±0.3 **** Comparative Example 2100 Comparative Example 378.8±17.6 Comparative Example 475.2±20.4 * Comparative example 567.6±16.4 ** Example 290.4±34.3 Example 380.1±5.9 Example 452.1±27.4 **** Example 540.5±6.6 **** Example 659.5±40.7 *** Example 862.0±15.8 **

[0108]

[0109] As can be seen in Table 5 and Figure 3, Example 3 showed about 20% inhibition compared to Comparative Example 2, and particularly, Example 4 showed 40-60% inhibition. In addition, compared to Example 8, which was administered at a high dose for a long time, Examples 4 to 6, which were administered at a low dose for 20 to 45 minutes, showed better inhibition results.

[0110]

[0111] 7. Experimental Example 4: Evaluation of the Effect on Inflammatory Factor Expression (IL-6)

[0112] The production of cytokine IL-6 was measured in the bronchial lung lavage fluids isolated from Examples 2 to 6 and 8 and Comparative Examples 1 to 5 using enzyme-linked immunosorbent assay (ELISA). The investigation method is as follows.

[0113] To measure the amount of IL-6 (M6000B, R&D systems, Minneapolis, USA) in bronchopulmonary washings, an ELISA kit was used. Lung washings obtained from experimental animals were stored in a deep freezer and then measured according to the manufacturer's protocol. After measuring the absorbance at 450 nm, the 540 nm measurement was corrected and used, and the measurement was performed using a SpectraMax i3x (Molecular devices, San Jose, CA, USA) device.

[0114] The results obtained from the above experiment were recorded as the mean ± standard deviation, and the P value was <0.05 ( * ) or <0.01( ** ) significance test was performed at the level below.

[0115] The results are shown in Table 6 below and Figure 4.

[0116]

[0117] Comparison of the group with the classification-induced group (%): 10.1±0.4 **** Comparative Example 2100 Example 2112.8±66.9 Example 356.3±34.1 * Example 429.4±21.3 *** Example 552.5±20.7 * Example 659.9±13.7 Example 872.0±22.5

[0118]

[0119] As can be seen in Table 6 and Fig. 4, Comparative Example 2 induced by PM10D showed an increase in the amount of IL-6, an inflammation-related indicator, compared to Comparative Example 1. However, in Examples 3 to 8, in which vitamin B5 was administered at 6 to 28 mg / kg, the amount of IL-6 tended to decrease, and a tendency for the amount of IL-6 to decrease was also confirmed compared to the oral administration group, Comparative Examples 3 to 5. In particular, Example 4, in which vitamin B5 10% was administered at 10 mg / kg, showed a clear decrease of more than 70%. In addition, compared to Example 8, in which a high dose was administered for a long time, a better decrease result was confirmed in Examples 3 to 6, in which a low dose was administered for 20 to 45 minutes.

[0120]

[0121] From the above experimental examples 1 to 4, it is predicted that by using the composition for improving respiratory health and treating or preventing respiratory diseases as described in the claims, a composition having an excellent effect of improving and treating respiratory inflammation can be provided even with a small dosage.

[0122]

[0123] Although the embodiments described above have been described with limited drawings, those skilled in the art will appreciate that various technical modifications and variations can be applied based on the above. For example, appropriate results can still be achieved even if the described techniques are performed in a different order than described, and / or components of the described systems, structures, devices, circuits, etc. are combined or combined in a different manner than described, or are replaced or substituted with other components or equivalents.

[0124]

[0125] Therefore, other implementations, other embodiments, and equivalents to the claims also fall within the scope of the claims described below.

Claims

1. A composition for improving respiratory health and treating or preventing respiratory diseases, containing vitamin B5 as an active ingredient.

2. In paragraph 1, The composition for improving respiratory health and treating or preventing respiratory diseases is a composition for improving respiratory health and treating or preventing respiratory diseases, which is applied to inflammation by inhalation or spraying.

3. In paragraph 2, The above inhalation or spray composition is applied to the oral or nasal cavity, for improving respiratory health and treating or preventing respiratory diseases.

4. In paragraph 2, The composition for improving respiratory health and treating or preventing respiratory diseases, wherein the above inhalation or spraying is applied by any one of ultrasound, spray, and nebulizing devices.

5. In paragraph 1, The composition for improving respiratory health and treating or preventing respiratory diseases is a liquid composition for improving respiratory health and treating or preventing respiratory diseases.

6. In paragraph 1, A composition for improving respiratory health and treating or preventing respiratory diseases, wherein the dosage of the composition for improving respiratory health and treating or preventing respiratory diseases is 1 mg / kg to 30 mg / kg.

7. In paragraph 1, A composition for improving respiratory health and treating or preventing respiratory diseases, wherein the concentration of the vitamin B5 is 2 wt% to 30 wt% based on the total weight of the composition for improving respiratory health and treating or preventing respiratory diseases.

8. In paragraph 1, A composition for improving respiratory health and treating or preventing respiratory diseases, wherein the administration time of the composition for improving respiratory health and treating or preventing respiratory diseases is 5 to 60 minutes.

9. In paragraph 1, A composition for improving respiratory health and treating or preventing respiratory diseases, wherein the respiratory diseases include at least one or more selected from the group consisting of allergies, bronchitis, sinusitis, lower respiratory tract infections, bronchiolitis, asthma, chronic obstructive pulmonary disease, rhinitis, pneumonia, emphysema, bronchiectasis, pulmonary fibrosis, cough, sputum, pharyngitis, tonsillitis and laryngitis.

10. A pharmaceutical composition for treating or preventing respiratory diseases, comprising a composition for improving respiratory health and treating or preventing respiratory diseases according to any one of claims 1 to 9.

11. A health functional food composition for improving respiratory health or respiratory disease, comprising a composition for improving respiratory health and treating or preventing respiratory disease according to any one of claims 1 to 9.

Images